MIF and Stroke: However, considering the above-said, those anti-MIF SMDs that are not membrane-penetrable—thus specifically directed at extracellular -job 2- MIFs—overall appear preferable, although exceptions may apply to applications in cancer and stroke, in which intracellular MIF has been suggested to exert detrimental effects as well (125, 131).